Baker Tilly Wealth Management LLC Has $1.33 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Baker Tilly Wealth Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 38.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,004 shares of the company's stock after buying an additional 2,221 shares during the quarter. Baker Tilly Wealth Management LLC's holdings in Johnson & Johnson were worth $1,327,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson in the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $32,000. Conquis Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter worth about $33,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $36,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ traded down $0.95 during mid-day trading on Tuesday, reaching $154.45. The company had a trading volume of 8,205,196 shares, compared to its average volume of 7,944,681. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market capitalization of $371.63 billion, a P/E ratio of 23.23, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company's 50-day moving average is $154.19 and its 200-day moving average is $153.67.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.37%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Raymond James lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Morgan Stanley lifted their price target on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.